Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217106 · ClinicalTrials.gov registry record
A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 342
- Enrollment target
NCT07217106 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 342 participants.
The verdict
NCT07217106 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 342 participants
- Enrollment target
Study Summary
The aim of the study was to evaluate the efficacy and safety of a Guideline-Directed Medical Therapy (GDMT) clinic within a general cardiology practice relative to usual care. This study analyzed data from patients with heart failure (HF) who were referred to the GDMT clinic at Massachusetts General Hospital (MGH). For the comparator arm, patients in the GDMT clinic were matched to data of patients contained within in the MGH Research Patient Data Repository (RPDR).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2024-03-03 |
| Est. Completion | 2024-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07217106
The ClinicalTrials.gov registry entry for NCT07217106 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07217106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07217106 about?
NCT07217106 is a clinical study titled "A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure". The aim of the study was to evaluate the efficacy and safety of a Guideline-Directed Medical Therapy (GDMT) clinic within a general cardiology practice relative to usual care. This study analyzed data from patients with heart failure (HF) who were referred to the GDMT clinic at Massachusetts General...
What is the current status of trial NCT07217106?
This trial is currently completed. The enrollment target is 342 participants. The study started on 2024-03-03. Estimated completion is 2024-07-01.
Who is sponsoring clinical trial NCT07217106?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.